

Rajeka Lazarus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10896547/publications.pdf>

Version: 2024-02-01

23
papers

8,926
citations

516561

16
h-index

677027

22
g-index

24
all docs

24
docs citations

24
times ranked

15743
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
3	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
4	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
5	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet, The</i> , 2021, 398, 856-869.	6.3	430
6	Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells. <i>Journal of Infectious Diseases</i> , 2012, 205, 1408-1416.	1.9	235
7	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
8	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. <i>Lancet, The</i> , 2022, 399, 36-49.	6.3	161
9	A Randomized Study Comparing Combined Pneumococcal Conjugate and Polysaccharide Vaccination Schedules in Adults. <i>Clinical Infectious Diseases</i> , 2011, 52, 736-742.	2.9	97
10	Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38) randomised, controlled, phase 4 trial. <i>Lancet, The</i> , 2021, 398, 2277-2287.	6.3	83
11	The risk of metachronous neoplasia in patients with serrated adenoma. <i>American Journal of Clinical Pathology</i> , 2005, 123, 349-59.	0.4	55
12	Estimating the COVID-19 epidemic trajectory and hospital capacity requirements in South West England: a mathematical modelling framework. <i>BMJ Open</i> , 2021, 11, e041536.	0.8	24
13	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 1049-1060.	5.2	24
14	Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. <i>Vaccine</i> , 2009, 27, 6918-6925.	1.7	20
15	The Effect of Chronic Cytomegalovirus Infection on Pneumococcal Vaccine Responses. <i>Journal of Infectious Diseases</i> , 2014, 209, 1635-1641.	1.9	19
16	Pneumococcal Polysaccharide Vaccine Efficacy and Routine Use of Conjugate Vaccines in Infants: There Is No Need for a Vaccine Program in Older Adults at Present. <i>Clinical Infectious Diseases</i> , 2012, 55, 1577-1579.	2.9	17
17	The zwitterionic type I <i>Streptococcus pneumoniae</i> polysaccharide does not induce memory B cell formation in humans. <i>Immunobiology</i> , 2013, 218, 368-372.	0.8	15
18	Use of Xpert MTB/RIF in a low prevalence setting in the Southwest of England. <i>Journal of Infection</i> , 2021, 82, 159-198.	1.7	15

#	ARTICLE	IF	CITATIONS
19	Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults. <i>Journal of Infection</i> , 2022, 85, 306-317.	1.7	12
20	Cutaneous Salmonella infection. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 257-258.	1.5	11
21	Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. <i>PLoS ONE</i> , 2016, 11, e0165384.	1.1	2
22	Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial. <i>Clinical and Translational Science</i> , 2021, , .	1.5	1
23	Testing for blood-borne viruses after a needle-stick injury in patients who lack the capacity to consent. <i>Clinical Medicine</i> , 2017, 17, 376-377.	0.8	0